Second study participant dies during Eisai’s Alzheimer’s drug trial November 28, 2022 AutoBot Uncategorized 0 A second study participant has died possibly as a result of the experimental antibody drug, lecanemab, meant to treat Alzheimer’s, Science reported Nov. 27.